On-Command Drug Release from Nanochains Inhibits Growth of Breast Tumors
| Autor: | Randall Toy, Ramamurthy Gopalakrishnan, Erik Schmidt, Mark A. Griswold, Christopher Shoup, Swetha Rao, Pubudu M. Peiris, Ruth A. Keri, Aaron Abramowski, Elizabeth Doolittle, Samantha Tucci, Aaron T. Mayer, Jenna Pansky, Morgan Tam, Efstathios Karathanasis, James P. Basilion, Peter Vicente, Lisa Bauer, Kaitlyn Murray |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Pathology
medicine.medical_specialty Luminescence Radio Waves medicine.medical_treatment Pharmacology toxicology Tumor burden Pharmaceutical Science Antineoplastic Agents Breast Neoplasms Article Polyethylene Glycols Breast tumor Mice medicine Animals Humans Bioluminescence imaging Pharmacology (medical) Doxorubicin Triple-negative breast cancer Adjuvants Pharmaceutic Pharmacology Mice Inbred BALB C Chemotherapy Antibiotics Antineoplastic Chemistry Organic Chemistry Mammary Neoplasms Experimental Survival Analysis Tumor Burden Drug release Cancer research Nanoparticles Molecular Medicine Female Biotechnology medicine.drug |
| Zdroj: | Pharmaceutical Research. 31:1460-1468 |
| ISSN: | 1573-904X 0724-8741 |
| DOI: | 10.1007/s11095-013-1102-8 |
| Popis: | To evaluate the ability of radiofrequency (RF)-triggered drug release from a multicomponent chain-shaped nanoparticle to inhibit the growth of an aggressive breast tumor.A two-step solid phase chemistry was employed to synthesize doxorubicin-loaded nanochains, which were composed of three iron oxide nanospheres and one doxorubicin-loaded liposome assembled in a 100-nm-long linear nanochain. The nanochains were tested in the 4T1-LUC-GFP orthotopic mouse model, which is a highly aggressive breast cancer model. The 4T1-LUC-GFP cell line stably expresses firefly luciferase, which allowed the non-invasive in vivo imaging of tumor response to the treatment using bioluminescence imaging (BLI).Longitudinal BLI imaging showed that a single nanochain treatment followed by application of RF resulted in an at least 100-fold lower BLI signal compared to the groups treated with nanochains (without RF) or free doxorubicin followed by RF. A statistically significant increase in survival time of the nanochain-treated animals followed by RF (64.3 days) was observed when compared to the nanochain-treated group without RF (35.7 days), free doxorubicin-treated group followed by RF (38.5 days), and the untreated group (30.5 days; n=5 animals per group).These studies showed that the combination of RF and nanochains has the potential to effectively treat highly aggressive cancers and prolong survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink